



1/18  
Fig. 1



BEST AVAILABLE COPY













2/18  
Fig. 2

**SK-N-SH**



3/18  
Fig. 3


*Annexin assay*

pEGFP-C2				293T
pEGFP-Cp				
pEGFP-C2				U2OS
pEGFP-Cp				

4/18  
Fig. 4


## ***FACS Analysis***

**pEGFP-C2**



**15.97%**


**pEGFP-Cp**



**27.03%**

**48h**


5/18  
Fig. 5



+Ade

-Ade/  
X-gal

6/18  
Fig. 6






7/18  
Fig. 7

Fig. 8


A

**B**




9/18

Fig. 9




10/18

Fig. 10




11/18

Fig. 11




12/18

Fig. 12




13/18

Fig. 13




14/18

Fig. 14




15/18

Fig. 15




16/18  
Fig. 16





17/18  
Fig. 17



18/18

Fig. 18

Control	Retrovirus
	stable cell line

